Seasonal influenza virus vaccine H1N1 intranasal - Altimmune
Alternative Names: NasoVAX™ Seasonal Influenza VaccineLatest Information Update: 28 Nov 2019
Price :
$50 *
At a glance
- Originator Vaxin
- Developer Altimmune
- Class COVID-19 vaccines; Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Intranasal, Spray)
- 08 Oct 2015 Altimmune plans a phase II trial for Influenza-A virus subtype H1N1 in USA
- 01 Sep 2015 Vaxin is now called Altimmune